Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018264 · ClinicalTrials.gov registry record · Phase 4
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
A Phase 4 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT01018264: Completed Phase 4 study, sponsored by University of South Florida.
NCT01018264 is a Phase 4 study that has completed, run by University of South Florida. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01018264, a Phase 4 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.
Primary Outcome
The primary objective of this study is to measure the efficacy of solifenacin succinate (VESIcare) in reducing the mean number of micturitions per 24 hour period in Parkinson's disease (PD) patients as measured by voiding diaries.
Interventions
- DRUG placebo
- DRUG solifenacin succinate (VESIcare)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
What the finished NCT01018264 record still lists
NCT01018264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01018264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01018264 about?
NCT01018264 is a clinical study titled "Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease". This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.
What is the current status of trial NCT01018264?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2010-01. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01018264?
The interventions under investigation include: placebo (DRUG), solifenacin succinate (VESIcare) (DRUG).
Who is sponsoring clinical trial NCT01018264?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01018264's enrollment target sits among peer trials
23 1725th of 2000 higher than 270 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia